July 2008
Worldwide Biotech;Jul2008, Vol. 20 Issue 7, p8
Trade Publication
The article reports the start of Phase II clinical trial of Ampligen (r) as seasonal flue vaccine enhancer has been completed by Hemispherx Biopharma Inc. in Australia. The company will evaluate the safety and efficacy of Ampligen (r) as an enhanser for seasonal flu vaccine. The secondary goal of the trial is to evaluate whether Ampligen (r) can provide cross-protection against other virus strains, including H5N1, the avian flu virus.


Related Articles

  • HEMISPHERX INITIATES AMPLIGEN PHASE IIB FOR INFLUENZA.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p2 

    The article reports that the Ampligen Phase IIB trial for influenza was initiated by the Hemispherx Biopharma, Inc. in Australia. The Japanese National Institute of Infectious Diseases (JIID) reported robust immune responses in animals when Ampligen (r) was added to either avian or seasonal...

  • Emory University to test vaccines against possible influenza pandemic.  // Infectious Disease News;Oct2008, Vol. 21 Issue 10, p19 

    The article reports on a clinical trial of a new avian influenza vaccine by the Emory Vaccine and Treatment Evaluation Unit by Emory University in Atlanta, Georgia, along with collaborators at the Mayo Clinic in Rochester, Minnesota. The trial will involve 500 healthy people who have not been...

  • CLINIC ROUNDUP.  // BioWorld Today;6/3/2008, Vol. 19 Issue 107, p12 

    This section offers news briefs on clinical trials of various drugs as of June 2008. AMAG Pharmaceuticals Inc. reported positive results from two Phase III studies of ferumoxytol as iron replacement therapeutic agent in patients with chronic kidney disease with functioning kidney transplants....

  • Chronic tonic.  // Pharmaceutical Executive;May98, Vol. 18 Issue 5, p134 

    Announces a Phase III clinical study of Hemispherx Biopharma's clinical study of its drug Ampligen. Details on the placebo-controlled study; Results of earlier trial.

  • A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine. Couch, Robert B.; Patel, Shital M.; Wade-Bowers, Chianti L.; NiƱo, Diane // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Background: Concern for a pandemic caused by a newly emerged avian influenza A virus has led to clinical trials with candidate vaccines as preparation for such an event. Most trials have involved vaccines for influenza A (H5N1), A (H7N7) or A (H9N2). Objective: To evaluate dosage-related safety...

  • New development.  // CMAJ: Canadian Medical Association Journal;4/11/2006, Vol. 174 Issue 8, p1080 

    The article focuses on the development of a new vaccine against influenza A subtype H5N1 or avian flu by Mary Holscher and colleagues. The vaccine is based on a nonreplicating human adenovirus that contains a gene from the H5N1 virus. They were able to grow the resulting vaccine in cell lines...

  • Pugh's view.  // Pulse;10/12/2006, Vol. 66 Issue 38, p9 

    A cartoon on bird flu vaccination of general practitioners is presented.

  • Iowa firm gets OK to make vaccine.  // Wallaces Farmer;Oct2015, Vol. 140 Issue 10, p66 

    The article informs that Harrisvaccines Inc., a company from Iowa, has received conditional approval from the U.S. Department of Agriculture (USDA) to manufacture avian influenza vaccine to prevent poultry from dying from the deadly avian influenza virus.

  • Avian Influenza Vaccine Licensed. CLAYTON, CHRIS // Progressive Farmer;Nov2015, Vol. 130 Issue 12, pPF-19 

    The article focuses on the conditional approval received by biotechnology company Harrisvaccines for production of vaccine for for bird flu.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics